Evaluating Low-Dose Carperitide for Acute Heart Failure: Insights from the LASCAR-AHF Trial and Nationwide Outcomes in Japan

MedXY Editorial Team•Oct 3, 2025•Cardiology

The LASCAR-AHF randomized trial showed low-dose intravenous carperitide did not improve 2-year mortality or hospitalization rates in acute heart failure (AHF) patients.
A nationwide cohort study from Japan revealed higher in-hospital mortality, longer hospital stays, and increased costs associated with carperitide compared to nitrates in early AHF treatment.
No significant improvements in dyspnoea, urine output, or biomarkers were observed with carperitide, and kidney function declined more in treated patients.
Routine use of carperitide as a first-line vasodilator for AHF is questionable, warranting further investigation and cautious clinical use.

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

The LASCAR-AHF randomized trial showed low-dose intravenous carperitide did not improve 2-year mortality or hospitalization rates in acute heart failure (AHF) patients.
A nationwide cohort study from Japan revealed higher in-hospital mortality, longer hospital stays, and increased costs associated with carperitide compared to nitrates in early AHF treatment.
No significant improvements in dyspnoea, urine output, or biomarkers were observed with carperitide, and kidney function declined more in treated patients.
Routine use of carperitide as a first-line vasodilator for AHF is questionable, warranting further investigation and cautious clinical use.